Zevra Therapeutics rises after H.C. Wainwright starts coverage with 'buy' rating

ReutersJul 2, 2025 12:07 PM

Rare disease-focused biopharmaceutical company Zevra Therapeutics' ZVRA.O shares up ~2.57% at $9.18 premarket

H.C. Wainwright initiates ZVRA coverage with "buy" rating, says stocks remains undervalued

Brokerage says the co is now positioned to reward investors as a leading rare disease company with commercial and development expertise

Sets PT at $26, a ~190.5% upside to stock's last close

All of eight brokerages rate the stock "buy" or higher; their median PT is $25 - LSEG

As of last close, stock up ~7.3% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

US-Iran Tensions Heat Up Again, Brent Crude Prices Return Above $100

TradingKey - Oil prices surge as US-Iran clashes resume following a brief de-escalation.

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

TradingKey - During the US market opening session on May 7, Tesla (TSLA.US) shares extended their rebound momentum, rising more than 2% at one point to open at $406, returning above the $400 level. On May 5 and 6, the stock touched the $400 mark intraday but closed below that threshold on both days.

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

TradingKey - On Wednesday (May 7), Anthropic reached an agreement with Elon Musk's SpaceX to access SpaceX's massive data center 'Colossus 1.' Meanwhile, Musk announced that xAI would be dissolved as an independent company and renamed SpaceXAI, becoming an AI product line within SpaceX. Can SpaceX's

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

With a sold-out HBM pipeline, leadership in G9 NAND technology, and a valuation that has yet to fully account for its 2030 trillion-dollar potential, Micron remains a cornerstone "buy" for any long-term tech portfolio.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools